July 31, 2013
by admin
7 Comments
Comparing the founding of two virtual drug development companies, Funxional Therapeutics in 2006 and XO1 earlier in 2013 proves at least one thing: in just seven years it has become dramatically easier and quicker to create a virtual drug development … Continue reading
July 29, 2013
by admin
8 Comments
As biotech companies queue up like lemmings on a cliff top to hurl themselves through the ‘IPO window’ while its open, DrugBaron tried (and failed) to understand the mentality of public market investors who shun biotech assets for years, and … Continue reading
July 16, 2013
by admin
5 Comments
In 2010, DrugBaron declared the death of incremental innovation and wrote the obituary. It didnt seem a very bold statement at the time – increasing payor pressure was beginning to bite, and it seemed obvious that the entrenched practice of … Continue reading